These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34403501)

  • 1. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma.
    Aboul-Enein MS; Knight W; Wulaningsih W; Foley DM; Dellaportas D; Zylstra J; Baker CR; Kelly M; Smyth E; Lagergren J; Maisey N; Allum WH; Gossage JA; Cunningham D; Davies AR;
    J Surg Oncol; 2021 Dec; 124(8):1296-1305. PubMed ID: 34403501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy followed by surgery for advanced oesophageal cancer.
    Toxopeus EL; Talman S; van der Gaast A; Spaander VM; van Rij CM; Krak NC; Biermann K; Tilanus HW; Mathijssen RH; van Lanschot JJ; Wijnhoven BP
    Eur J Surg Oncol; 2015 Mar; 41(3):323-32. PubMed ID: 25534280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer.
    Kano K; Aoyama T; Yoshikawa T; Maezawa Y; Nakajima T; Hayashi T; Yamada T; Sato T; Oshima T; Rino Y; Masuda M; Cho H; Ogata T
    Ann Surg Oncol; 2018 Jul; 25(7):2034-2043. PubMed ID: 29748890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
    Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
    Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions.
    Erhunmwunsee L; Englum BR; Onaitis MW; D'Amico TA; Berry MF
    Ann Surg Oncol; 2015 Mar; 22(3):1020-5. PubMed ID: 25234017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
    Spence AD; Trainor J; McMenamin Ú; Turkington RC; McQuaid S; Bingham V; James J; Salto-Tellez M; McManus DT; Johnston BT; Cardwell CR; Coleman HG
    Histopathology; 2019 Mar; 74(4):587-596. PubMed ID: 30408225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
    Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
    Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.
    Bott RK; Beckmann K; Zylstra J; Wilkinson MJ; Knight WRC; Baker CR; Kelly M; Maisey N; Qureshi A; Sevitt T; Van Hemelrijck M; Smyth EC; Allum WH; Lagergren J; Gossage JA; Cunningham D; Davies AR;
    Br J Surg; 2020 Dec; 107(13):1801-1810. PubMed ID: 32990343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
    Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
    Jagadesham VP; Lagarde SM; Immanuel A; Griffin SM
    Br J Surg; 2017 Mar; 104(4):401-407. PubMed ID: 28072456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Miyata H; Tanaka K; Makino T; Yamasaki M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Morii E; Mori M; Doki Y
    Ann Surg Oncol; 2018 Aug; 25(8):2409-2417. PubMed ID: 29748887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
    Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
    Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.